Hong Y.,Mokwon University |
Kim M.-Y.,AngioLab Inc. |
Yoon M.,Mokwon University
Pharmaceutical Biology | Year: 2011
Context: Growing adipose tissue is thought to require adipogenesis, angiogenesis, and extracellular matrix (ECM) remodeling. Close examination of developing adipose tissue microvasculature reveals that angiogenesis often precedes adipogenesis. Since our previous study demonstrated that Ob-X, the anti-angiogenic herbal composition composed of Melissa officinalis L. (Labiatae), Morus alba L. (Moraceae), and Artemisia capillaris Thunb. (Compositae), reduced adipose tissue mass in obese mice, we hypothesized that adipogenesis can be inhibited by Ob-X. Objective: To investigate the effects of the anti-angiogenic herbal extracts Ob-X on adipogenesis in 3T3-L1 adipocytes. Materials and methods: After differentiated 3T3-L1 adipocytes were treated with Ob-X, we studied the effects of Ob-X on triglyceride accumulation and expression of genes involved in adipogenesis, angiogenesis, and ECM remodeling. Results: Treatment of cells with Ob-X inhibited lipid accumulation and adipocyte-specific gene expression caused by troglitazone or monocyte differentiation-inducing (MDI) mix. Ob-X reduced mRNA levels of angiogenic factors (vascular endothelial growth factor-A, -B, -C, -D, and fibroblast growth factor-2) and matrix metalloproteinases (MMPs; MMP-2 and MMP-9), whereas it increased mRNA levels of angiogenic inhibitors [(thrombospondin-1, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2)] in differentiated cells. MMP-2 and MMP-9 activities were also decreased in Ob-X-treated cells. Discussion and conclusion: These results suggest that the anti-angiogenic herbal composition Ob-X inhibits differentiation of preadipocytes into adipocytes. These events may be mediated by changes in the expression of genes involved in lipogenesis, angiogenesis, and the MMP system. Thus, by reducing adipogenesis, anti-angiogenic Ob-X provides a possible therapeutic approach for the prevention and treatment of human obesity and its related disorders. © 2011 Informa Healthcare USA, Inc. Source
Yoon M.,Mokwon University |
Kim M.-Y.,AngioLab Inc.
Pharmaceutical Biology | Year: 2011
Context: The growth and development of adipose tissue leading to obesity is suggested to depend on angiogenesis. Our previous study showed that Melissa officinalis L. (Labiatae), Morus alba L. (Moraceae), and Artemisia capillaris Thunb. (Compositae) are involved in the regulation of angiogenesis. We hypothesized that Ob-X, a mixture of three herbs, M. alba, M. officinalis, and A. capillaris, can regulate obesity. Objective: To investigate the inhibitory effect of Ob-X on obesity in genetically obese ob/ob mice. Materials and methods: The effect of Ob-X on angiogenesis was measured using a mouse Matrigel plug assay. The effects of Ob-X on obesity were investigated in ob/ob mice. Results: Ob-X inhibited angiogenesis in a dose-dependent manner, as evidenced by decreased blood vessel density in a mouse matrigel plug assay. Administration of Ob-X to ob/ob mice for 5 weeks produced a significant reduction in body weight gain by 27% compared with control (12.1±3.01 vs. 16.6±2.24g, respectively). Ob-X also significantly decreased visceral adipose tissue mass by 15% (0.87±0.12 vs. 1.02±0.15g, respectively). The size of adipocytes in visceral adipose tissue was reduced by 46% in Ob-X-treated mice. Ob-X treatment inhibited hepatic lipid accumulation and significantly decreased circulating glucose levels compared with controls (197±56.5 vs. 365±115mg/dL, respectively). Discussion and conclusion: These results suggest that Ob-X, which has an anti-angiogenic activity, reduces body weight gain and visceral adipose tissue mass in genetically obese mice, providing evidence that obesity can be prevented by angiogenesis inhibitors. © 2011 Informa Healthcare USA, Inc. Source
Kang W.K.,Chungnam National University |
Lee M.H.,Chungnam National University |
Kim Y.H.,Chungnam National University |
Kim M.Y.,AngioLab Inc. |
Kim J.-Y.,Chungnam National University
Journal of Biotechnology | Year: 2013
Vascular endothelial growth factor (VEGF) mediates angiogenesis, which plays a critical role in the development and differentiation of the vascular system. VEGF is a homodimeric glycoprotein that contains one N-glycosylation site. In this study, we evaluated Saccharomyces cerevisiae expression systems producing glycosylated and non-glycosylated splice variants of human VEGF, VEGF121, and VEGF165. The pre region of the mating factor α1 (MFα1) signal sequence was found to perform better than the entire MFα1 prepro signal sequence in secreting glycosylated VEGF. Secretion of non-glycosylated VEGF165 was completely blocked, indicating the importance of glycosylation in VEGF165 secretion. Interestingly, non-glycosylated VEGF165 was secreted when guided by the MFα1 prepro signal sequence, albeit to a lesser degree, compared to glycosylated VEGF165. N-glycosylation in the pro region was required for the prepro sequence to promote VEGF secretion. Furthermore, substitution of asparagine at the VEGF glycosylation site with lysine or glutamic acid increased secretion of non-glycosylated VEGF, a finding not previously reported. Our findings suggest that S. cerevisiae could be a suitable host for secreting biologically active, non-glycosylated VEGF for clinical use. © 2013 Elsevier B.V. Source
Angiolab. Inc. | Date: 2012-09-11
Pharmaceutical preparations for the treatment of angiogenesis-dependent diseases, namely, obesity, cancer, arthritis, psoriasis, and ocular diseases, and diagnostic preparations for veterinary use for the treatment of angiogenesis-dependent diseases; dietary supplements and dietetic foods adapted for medical use for the treatment of angiogenesis-dependent diseases, namely, obesity, cancer, arthritis, psoriasis, and ocular diseases.
AngioLab. Inc. | Date: 2016-06-13
Tea extracts for the food industry; tea extracts for use in the manufacture of pharmaceuticals and cosmetics; botanical extracts, plant extracts, and herb extracts, other than essential oils, for use in the manufacture of cosmetics; plant extracts, herb extracts, tea extracts for use in the manufacturing of dietary supplements, nutritional products, pharmaceuticals and cosmetics; phytochemicals for use in the manufacturing of dietary supplements, nutritional products, pharmaceuticals and cosmetics. Food and herbal supplements; dietary and nutritional supplements; nutraceuticals for use as dietary supplements; dietetic food supplements; dietary supplements for human consumption.